{"id":45298,"date":"2022-06-21T13:02:03","date_gmt":"2022-06-21T11:02:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/affinivax-presents-data-for-enhanced-protection-against-serotype-3-in-next-generation-pneumococcal-vaccine\/"},"modified":"2022-06-21T13:02:03","modified_gmt":"2022-06-21T11:02:03","slug":"affinivax-presents-data-for-enhanced-protection-against-serotype-3-in-next-generation-pneumococcal-vaccine","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/affinivax-presents-data-for-enhanced-protection-against-serotype-3-in-next-generation-pneumococcal-vaccine\/","title":{"rendered":"Affinivax Presents Data for Enhanced Protection Against Serotype 3 in Next-Generation Pneumococcal Vaccine"},"content":{"rendered":"
\n

\n\u2013 Preclinical data show synergistic protective effect of anti-protein and anti-polysaccharide antibodies in a highly virulent model of serotype 3 invasive pneumococcal disease \u2013\n<\/p>\n

\n\u2013 Presentation at the 12th International Symposium on Pneumococci and Pneumococcal Diseases \u2013\n<\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Affinivax, Inc.<\/a> (\u201cAffinivax\u201d), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS\u2122 (Multiple Antigen Presenting System) platform<\/a>, announced the company is presenting preclinical data demonstrating that a next generation pneumococcal vaccine candidate incorporating a novel pneumococcal fusion protein conferred enhanced protection in a highly virulent model of serotype 3 invasive pneumococcal disease, at the 12th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-12) taking place on June 19-23 in Toronto.\n<\/p>\n

<\/a><\/p>\n

\n\u201cThe continued threat of Streptococcus pneumoniae <\/i>in both the developed and developing world requires further innovation and novel strategies to provide enhanced protection against this pathogen,\u201d said Rick Malley, MD, Chief Scientific Officer and Scientific Founder of Affinivax. \u201cSerotype 3, in particular, has proven resistant to the effects of traditional conjugate vaccines. These new data presented by Affinivax reveal that the inclusion of a new conserved pneumococcal fusion protein using our versatile MAPS technology has the potential for next generation MAPS pneumococcal vaccines to enable enhanced protection against this serotype and provide broader coverage to patients.\u201d\n<\/p>\n

\nStreptococcus <\/i>pneumoniae <\/i>causes pneumonia, bacteremia and meningitis, especially in infant and older adult populations. Over 100 different serotypes, characterized by diverse capsular polysaccharides (CPS) which surround the pneumococcal bacterium, have been identified. Serotype 3, a major cause of morbidity and mortality worldwide, is a serotype resistant to anti-CPS antibody-mediated protection; the incidence rates of serotype 3 invasive pneumococcal disease have not significantly declined following the introduction of 13-valent pneumococcal conjugate vaccines1<\/sup>.\n<\/p>\n

\nHighlights from the poster presentation, entitled \u201cSynergistic protective effect of antibodies against polysaccharide type 3 and pneumococcal proteins in a highly virulent type 3 invasive disease model in mice,\u201d are as follows:\n<\/p>\n